FDA safety alert: Efficacy concerns for a combination therapy in breast cancer treatment
Officials from the Food and Drug Administration (FDA) issued a safety alert on Sept. 8 about potential efficacy and safety concerns with Tecentriq in combination with Paclitaxel for breast cancer treatment.
A clinical trial that studied the use of atezolizumab (Tecentriq)and paclitaxel versus a placebo and Paclitaxel to treat metastatic triple-negative breast cancer found that the combination therapy did not significantly reduce the risk of cancer progression and death when compared with placebo and paclitaxel in the PD-L1-positive population.
In addition, interim overall survival results favored paclitaxel plus placebo over paclitaxel plus atezolizumab in both the PD-L1-positive population and the total population.
The FDA urged that health care professionals should not replace paclitaxel protein-bound with paclitaxel in clinical practice.
For more information, visit DrugTopics.com.
Integrating HCV screening with breast cancer programs enhances care
June 25th 2024A recent study from France demonstrates that incorporating hepatitis C virus screening into breast cancer programs significantly improves patient engagement and access to effective antiviral treatments among older women.
Read More
